日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Reduction of Salmonella gallinarum in poultry with phage-based interventions

利用噬菌体干预措施减少家禽中的鸡沙门氏菌

Rehman, Saud Ur; Tariq, Hafsa; Evans, Audrey; Nazir, Iqra; Upatising, Varisra; Rehman, Shafiq Ur; Hayat, Zafar; Pencek, Tatum; Yamate, Kristen; Ebner, Paul

Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis

奥贝胆酸与原发性胆汁性胆管炎患者的AST/血小板比值指数和GLOBE评分的改善相关。

Harms, Maren H; Hirschfield, Gideon M; Floreani, Annarosa; Mayo, Marlyn J; Parés, Albert; Liberman, Alexander; Malecha, Elizabeth Smoot; Pencek, Richard; MacConell, Leigh; Hansen, Bettina E

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis

一项关于奥贝胆酸治疗原发性硬化性胆管炎的随机、安慰剂对照 II 期研究

Kowdley, Kris V; Vuppalanchi, Raj; Levy, Cynthia; Floreani, Annarosa; Andreone, Pietro; LaRusso, Nicholas F; Shrestha, Roshan; Trotter, James; Goldberg, David; Rushbrook, Simon; Hirschfield, Gideon M; Schiano, Thomas; Jin, Yuying; Pencek, Richard; MacConell, Leigh; Shapiro, David; Bowlus, Christopher L

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

奥贝胆酸单药治疗原发性胆汁性胆管炎患者的随机试验

Kowdley, Kris V; Luketic, Velimir; Chapman, Roger; Hirschfield, Gideon M; Poupon, Raoul; Schramm, Christoph; Vincent, Catherine; Rust, Christian; Parés, Albert; Mason, Andrew; Marschall, Hanns-Ulrich; Shapiro, David; Adorini, Luciano; Sciacca, Cathi; Beecher-Jones, Tessa; Böhm, Olaf; Pencek, Richard; Jones, David

Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis

GLOBE 和英国原发性胆汁性胆管炎风险评分在原发性胆汁性胆管炎患者试验队列中的临床应用

Carbone, Marco; Harms, Maren H; Lammers, Willem J; Marmon, Tonya; Pencek, Richard; MacConell, Leigh; Shapiro, David; Jones, David E; Mells, George F; Hansen, Bettina E

Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes

每周一次使用艾塞那肽治疗2型糖尿病患者,体重变化、血糖控制和心血管风险指标之间的关联:一项汇总分析

Blonde, Lawrence; Pencek, Richard; MacConell, Leigh

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years

每周一次艾塞那肽:3 年内持续改善血糖控制和心血管代谢指标

Macconell, Leigh; Pencek, Richard; Li, Yan; Maggs, David; Porter, Lisa

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes

比较2型糖尿病患者持续(每周一次艾塞那肽)或间歇(每日两次艾塞那肽)GLP-1受体激动剂治疗的安全性和耐受性

Ridge, T; Moretto, T; MacConell, L; Pencek, R; Han, J; Schulteis, C; Porter, L

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis

艾塞那肽每周一次、胰岛素和吡格列酮治疗2型糖尿病的健康和经济结果:一项模拟分析

Gaebler, Julia A; Soto-Campos, Gerardo; Alperin, Peter; Cohen, Marc; Blickensderfer, Amy; Wintle, Matthew; Maggs, David; Hoogwerf, Byron; Han, Jenny; Pencek, Richard; Peskin, Barbara

Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations

每周一次艾塞那肽治疗2型糖尿病:患者亚群的有效性和耐受性

Pencek, R; Blickensderfer, A; Li, Y; Brunell, S C; Chen, S